Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accumulated Depreciation (2019 - 2022)

Historic Accumulated Depreciation for C4 Therapeutics (CCCC) over the last 4 years, with Q1 2022 value amounting to $7.2 million.

  • C4 Therapeutics' Accumulated Depreciation rose 1777.08% to $7.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $7.2 million, marking a year-over-year increase of 1777.08%. This contributed to the annual value of $6.9 million for FY2021, which is 2279.83% up from last year.
  • According to the latest figures from Q1 2022, C4 Therapeutics' Accumulated Depreciation is $7.2 million, which was up 1777.08% from $6.9 million recorded in Q4 2021.
  • C4 Therapeutics' 5-year Accumulated Depreciation high stood at $7.2 million for Q1 2022, and its period low was $4.0 million during Q4 2019.
  • For the 4-year period, C4 Therapeutics' Accumulated Depreciation averaged around $6.0 million, with its median value being $6.3 million (2021).
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first skyrocketed by 4243.8% in 2020, then surged by 1777.08% in 2022.
  • C4 Therapeutics' Accumulated Depreciation (Quarter) stood at $4.0 million in 2019, then skyrocketed by 42.44% to $5.6 million in 2020, then grew by 22.8% to $6.9 million in 2021, then rose by 3.59% to $7.2 million in 2022.
  • Its Accumulated Depreciation was $7.2 million in Q1 2022, compared to $6.9 million in Q4 2021 and $6.8 million in Q3 2021.